Pay in 4 interest-free payments of $6.31 Learn more
Ships within 48 hours · Estimated delivery Aug 19 - Aug 24
sets 2025 sales target at US$ 57 billion Johnson & Johnson has forecast its revenue growth in 2024 to come in at between 5 and 6 percent over strong demand for its cancer therapies Darzalex (daratumumab) and Carvykti (ciltacabtagene autoleucel) as well as its blockbuster Stelara (ustekinumab) used to treat psoriasis
doi: 10.3389/fmed.2021.688486 52 HoarauJ-JJaffar BandjeeM-CKrejbich TrototPDasTLi-Pat-YuenGDassaBet al
Wish you the best in health & healing
For now, consulting a physician and using a licensed pharmacy can reduce some risks, particularly the danger of contamination or receiving the wrong substance
US$ 26.44
US$ 22.51
US$ 25.39
US$ 24.84
